A MicroRNA targeting dicer for metastasis control.

By Graziano Martello, Antonio Rosato, Francesco Ferrari, Andrea Manfrin, M. Cordenonsi, S. Dupont, E. Enzo, V. Guzzardo, M. Rondina, Thomas Spruce and 4 more. Cell, 2010

702 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6a5e7746cae63eb1e51a85b10bdb004e4627fddb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy (2011, positive): “Overexpression of miRNAs or reductions in transcription factors that specifically regulate DICER (discussed below”
The microcosmos of cancer (2012, background): “Conversely, in head and neck squamous-cell carcinomas, lung adenocarcinomas and breast cancers, the reduced levels of certain miRNAs that arise from Dicer1 downregulation also promote cell motility and are associated with enhanced metastasis in experimental model”
microRNAs in action: biogenesis, function and regulation (2023, background): “For example, auto-targeting of Dicer by miRNAs is relevant in certain cancers 130,131 , and other miRNA factors are preferentially targeted by miRNAs 132 .”
RNA-Binding Proteins in Cancer: Old Players and New Actors. (2017, background): “DICER1 itself is subject to repressive control by members of the let-7 miRNA family in lung cancer cell lines [52], and by miR-103 and miR-107 in breast cancer cells [53], attenuating miRNA biosynthesis and leading to metastasis in mouse models.”
A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis. (2015, result): “Among them, miR-103 and miR-107 displayed an opposite expression pattern versus NKILA, as their levels were much higher in high-metastatic than low-metastatic breast cancer cells (Figure S2E), which is consistent with a previous report (Martello et al., 2010).”
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review (2012, neutral): “To make it even more complicated, recently Piccolo’s group (Martello et al, 2010) described a microRNA family, miR-103-107, able to empower the metastatic potential targeting Dicer and thus attenuating the global microRNA biosynthetis, with a particular effect mediated by the downregulation of…”